window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : June 17, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Neurology

  • Advanced Therapies,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Skyhawk reports encouraging 12-month Huntington’s disease data for SKY-0515

    Skyhawk Therapeutics has reported encouraging 12-month results from its ongoing [...]

    June 6, 2026
  • Digital & Data,Drug Discovery & Development

    Promise Bio launches grant to support translational epiproteomics in biotech research

    Promise Bio has launched the Frontier Epiproteomic Innovation Grant, providing [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Therapeutic Areas

    Veristat names Kim McLean Boericke as CEO to drive next phase of clinical research growtheristat names Kim McLean Boericke as CEO to drive next phase of clinical research growth

    Veristat, a global clinical research organization (CRO) and consultancy specializing [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Drug Delivery & Formulation,Pharmaceuticals and therapeutics,Therapeutic Areas

    Neuraxpharm launches next-generation oral fumarate Riulvy for multiple sclerosis in Germany

    Neuraxpharm Group has launched Riulvy (tegomil fumarate) in Germany, marking [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Opinion & Events

    New Alzheimer’s guideline recommends blood biomarkers for more accessible diagnosis

    In a significant shift for Alzheimer’s care, the Alzheimer’s Association [...]

    May 5, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Opinion & Events,Therapeutic Areas

    MHRA approves Biogen’s tofersen for ultra-rare genetic form of motor neurone disease

    The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has [...]

    May 5, 2026
  • Advanced Therapies,Biotech & Pharma Business,Manufacturing & Supply Chain

    SpliceBio secures $135 Million series B to advance dual-AAV therapy for Stargardt Disease

    Funding will support clinical development of SB-007 and expand pipeline [...]

    May 5, 2026
  • Biotech & Pharma Business

    PacBio Joins Davos Alzheimer’s collaborative to expand dementia research in North Africa

    PacBio has been selected as a technology partner by the [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Elicio misses Phase 2 endpoint but advances Phase 3 plan for pancreatic cancer immunotherapy
    Categories: Clinical & Regulatory, Drug Discovery & Development, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Context reports 29% response rate for CTIM-76 in platinum-resistant ovarian cancer
    Categories: Advanced Therapies, Clinical & Regulatory, Pharmaceuticals and therapeutics, Therapeutic Areas
  • VIVEbiotech expands in vivo lentiviral vector portfolio to 15 programmes
    Categories: Advanced Therapies, Biotech & Pharma Business, Manufacturing & Supply Chain
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top